List view / Grid view
26 February 2015 | By GlobalData
The global market for atrial fibrillation (AF) treatment will more than double in value from $4.6 billion in 2013 to peak sales of $9.4 billion in 2020, before declining to $5.7 billion by 2023 as new oral anticoagulants (NOACs) become genericized, according to research and consulting firm GlobalData...
26 February 2015 | By Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...
25 February 2015 | By Turing Pharmaceuticals
Turing launches with three major product acquisitions: intranasal ketamine program, Syntocinon® Nasal Spray, and Vecamyl®; company introduces senior leadership team...
25 February 2015 | By Medical Research Council
Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England...
25 February 2015 | By Ipsen / Canbex Therapeutics Ltd
Ipsen and Canbex Therapeutics Ltd announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R...
25 February 2015 | By British Generic Manufacturers Association
The onset of biosimilar competition in the UK in Infliximab is another significant milestone in the development of the sector in this country according to the British Generic Manufacturers Association (BGMA).
24 February 2015 | By Janssen
2015 NHS Innovation Challenge prize winners announced...
24 February 2015 | By UCB
UCB announced that the company’s newly appointed Chief Executive Officer, Jean-Christophe Tellier, has been selected to join the Ministerial Industry Strategy Group...
24 February 2015 | By GBI Research
While drug candidates for Alzheimer’s Disease fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research...
24 February 2015 | By Kuros
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947...
24 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb is to expand its immuno-oncology pipeline with the aquisition of Flexus Biosciences in a deal worth up to $1.25 billion...
24 February 2015 | By Merck KGaA
Merck, in collaboration with Maharashtra University and University of Indonesia, is introducing European Accredited Clinical Diabetes management for more than 5000 medical and pharmacy students of both universities as part of Merck Capacity Advancement Program in Asia...
23 February 2015 | By Eli Lilly & Company
Eli Lilly and Company announced a delay in the submission of basal insulin peglispro (BIL) to regulatory agencies beyond the first quarter of 2015...
23 February 2015 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, has posted its full-year 2014 results...
23 February 2015 | By Persistence Market Research
North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market...
